EAACI Congress 2025
BackL-OAS03 - Clinical Immunology
Friday 13 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Carron 1
Oral Abstract Sessions
12:00
Primary and Safety Outcomes of a Phase 3, Open-Label, Single-Arm, 12-Week Study of Treatment with PI3Kδ Inhibitor Leniolisib in Paediatric Patients Aged 4–11 Years With Activated PI3Kδ Syndrome (APDS)
12:12
Long-Term Immunological Changes After Corrective Cardiac Surgery
12:24
AllergoOncology: Non-allergic urticarial skin reactions associated with MOv18 IgE, a first-in-class IgE antibody recognizing Folate Receptor alpha (FR⍺)
12:36
AllergoOncology and Glioblastoma: NR1D2 Activation Reprograms Tumor-Associated Macrophages and Limits Immunosuppression
12:48
Duodenal T cell Profiling in Patients with Primary Antibody Deficiencies: Associations with Enteropathy
